digital pill
The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry.
Also: Centauri Health Solutions acquires HCFS; UCSF researchers detail smartphone PPG-based diabetes detection.
The news comes months after reports that the company had furloughed staff and couldn't secure additional funding for its-ingestible sensor business.
The pharma company walks away with the full license for Proteus' mental health treatment adherence technology.
The sensor-embedded pill will be used to treat and monitor colorectal cancer patients receiving care at Fairview Health Services.
As the Abilify MyCite platform nears a full rollout, the companies said they are looking forward to employing the technology toward additional mental health therapies.
The ingesitble sensors will let providers look at adherence habits, activity levels and resting heart rate within a younger patient population.
The two companies are planning a limited initial deployment to gather additional real-world data before a wider release.
Proteus Digital Health’ pitch to track adherence using sensor-equipped pills has found another audience in the HIV prevention community.
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare.